Rhythm Pharmaceuticals (RYTM) Projected to Post Earnings on Tuesday

Key Points

• Rhythm Pharmaceuticals is expected to report Q3 2026 results before the market opens on November 3. Analysts forecast a loss of $0.71 per share and revenue of $85.47 million.
• The company exceeded expectations in the prior quarter, reporting a $0.73 per-share loss versus the $0.81 estimate and $71.25 million in revenue, up 46.9% year over year.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $142.50, compared with the stock’s recent price of $89.47.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Rhythm Pharmaceuticals to announce earnings of ($0.7101) per share and revenue of $85.47 million for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.73) earnings per share for the quarter, topping analysts' consensus estimates of ($0.81) by $0.08. Rhythm Pharmaceuticals had a negative return on equity of 159.87% and a negative net margin of 85.59%. The company had revenue of $71.25 million for the quarter, compared to analyst estimates of $67.66 million. During the same quarter last year, the company earned ($0.75) earnings per share. The firm's quarterly revenue was up 46.9% compared to the same quarter last year. On average, analysts expect Rhythm Pharmaceuticals to post ($2.77) EPS for the current fiscal year and ($0.49) EPS for the next fiscal year.

Rhythm Pharmaceuticals Trading Up 0.2%

Shares of RYTM opened at $89.47 on Tuesday. The stock has a market capitalization of $6.13 billion, a PE ratio of -28.77 and a beta of 2.01. Rhythm Pharmaceuticals has a 12 month low of $74.50 and a 12 month high of $122.20. The firm's 50 day moving average is $98.89 and its 200-day moving average is $97.54.

Analyst Ratings Changes

Several research firms have commented on RYTM. National Bank Financial set a $160.00 target price on shares of Rhythm Pharmaceuticals in a report on Wednesday, August 5th. Citizens Jmp increased their price target on shares of Rhythm Pharmaceuticals from $155.00 to $160.00 and gave the stock a "market outperform" rating in a research report on Wednesday, August 5th. JPMorgan Chase & Co. decreased their price objective on shares of Rhythm Pharmaceuticals from $146.00 to $145.00 and set an "overweight" rating on the stock in a research note on Thursday, October 15th. Wolfe Research began coverage on shares of Rhythm Pharmaceuticals in a research report on Thursday, September 17th. They set an "outperform" rating for the company. Finally, Citigroup restated a "market outperform" rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, August 5th. Eighteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $142.50.

Insider Transactions at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 5,079 shares of the business's stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $119.75, for a total transaction of $608,210.25. Following the sale, the insider owned 15,915 shares of the company's stock, valued at approximately $1,905,821.25. The trade was a 24.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO David Meeker sold 50,000 shares of the company's stock in a transaction on Monday, September 14th. The stock was sold at an average price of $102.67, for a total transaction of $5,133,500.00. Following the transaction, the chief executive officer owned 239,258 shares of the company's stock, valued at $24,564,618.86. This trade represents a 17.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 258,450 shares of company stock valued at $28,796,497. Corporate insiders own 5.90% of the company's stock.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases of obesity and related metabolic disorders. The company's work is based on the melanocortin-4 receptor (MC4R) pathway, which plays an important role in regulating hunger and energy balance.

Rhythm's principal product is IMCIVREE (setmelanotide), a targeted therapy designed to restore impaired MC4R pathway signaling. In the United States, IMCIVREE is approved for chronic weight management in adults and children at least 6 years old with obesity caused by certain genetic deficiencies, including POMC, PCSK1, or LEPR deficiency, as well as Bardet-Biedl syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.